147 related articles for article (PubMed ID: 32782230)
1. Changes in serum perampanel concentration profile after discontinuation of carbamazepine.
Murugesu S; Okayama K; Yamamoto Y; Terada K; Takahashi Y
Epileptic Disord; 2020 Aug; 22(4):455-461. PubMed ID: 32782230
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
[TBL] [Abstract][Full Text] [Related]
3. Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuation.
Schuck E; Ferry J; Gidal B; Hussein Z
Acta Neurol Scand; 2020 Aug; 142(2):131-138. PubMed ID: 32430908
[TBL] [Abstract][Full Text] [Related]
4. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
Yamamoto Y; Shiratani Y; Asai S; Usui N; Nishida T; Imai K; Kagawa Y; Takahashi Y
Seizure; 2020 Dec; 83():181-186. PubMed ID: 33171342
[TBL] [Abstract][Full Text] [Related]
6. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
7. Influence of Inflammation on the Pharmacokinetics of Perampanel.
Yamamoto Y; Takahashi Y; Horino A; Usui N; Nishida T; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2018 Dec; 40(6):725-729. PubMed ID: 30086086
[TBL] [Abstract][Full Text] [Related]
8. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
9. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience of abrupt discontinuation of perampanel: a case series.
Blickhan M; Intravooth T; Staack AM; Kornmeier R; Mahn P; Schneider M; Stockinger J; Bacher M; Kurth C; Steinhoff BJ
Epileptic Disord; 2021 Feb; 23(1):148-152. PubMed ID: 33602660
[TBL] [Abstract][Full Text] [Related]
12. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures.
Villanueva V; Majid O; Nabangchang C; Yang H; Laurenza A; Ferry J; Hussein Z
Epilepsy Res; 2016 Nov; 127():126-134. PubMed ID: 27595590
[TBL] [Abstract][Full Text] [Related]
14. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
17. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.
Laurenza A; Yang H; Williams B; Zhou S; Ferry J
Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193
[TBL] [Abstract][Full Text] [Related]
18. Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients.
Sabença R; Bicker J; Silva R; Carona A; Silva A; Santana I; Sales F; Falcão A; Fortuna A
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122491. PubMed ID: 33360678
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
[TBL] [Abstract][Full Text] [Related]
20. The adverse event profile of perampanel: meta-analysis of randomized controlled trials.
Zaccara G; Giovannelli F; Cincotta M; Verrotti A; Grillo E
Eur J Neurol; 2013 Aug; 20(8):1204-11. PubMed ID: 23607817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
